Endeavor Private Wealth Inc. Acquires New Stake in Amgen Inc. (NASDAQ:AMGN)

Endeavor Private Wealth Inc. bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 576 shares of the medical research company’s stock, valued at approximately $150,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Capital Performance Advisors LLP acquired a new stake in Amgen during the 3rd quarter worth approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 3rd quarter valued at about $29,000. Hershey Financial Advisers LLC acquired a new stake in Amgen in the 2nd quarter valued at about $30,000. Matrix Trust Co purchased a new position in shares of Amgen in the 3rd quarter valued at about $36,000. Finally, Livelsberger Financial Advisory acquired a new position in shares of Amgen during the third quarter worth about $56,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 0.5 %

Shares of Amgen stock opened at $273.44 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market cap of $146.98 billion, a price-to-earnings ratio of 35.01, a price-to-earnings-growth ratio of 2.79 and a beta of 0.56. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company’s 50-day simple moving average is $271.91 and its 200-day simple moving average is $306.43.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.96 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.48%. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is presently 115.24%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AMGN. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Piper Sandler dropped their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Robert W. Baird restated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a research note on Wednesday, September 25th. Leerink Partners lowered their price objective on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Barclays raised their target price on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.